Recombinant Human CNRIP1, N-His

Introduction to Recombinant Human CNRIP1

Recombinant Human CNRIP1, also known as cannabinoid receptor interacting protein 1, is a protein that plays a crucial role in the endocannabinoid system. This protein is involved in the modulation of cannabinoid receptor signaling and has been identified as a potential therapeutic target for various diseases. In this article, we will explore the structure, activity, and potential applications of Recombinant Human CNRIP1.

Structure of Recombinant Human CNRIP1

Recombinant Human CNRIP1 is a 35 kDa protein that consists of 314 amino acids. It is encoded by the CNRIP1 gene located on chromosome 10 in humans. The protein contains several domains, including an N-terminal leucine zipper motif, a central coiled-coil domain, and a C-terminal proline-rich domain. These domains are important for the protein’s interaction with other proteins and its function in the endocannabinoid system.

Activity of Recombinant Human CNRIP1

Recombinant Human CNRIP1 is primarily known for its role in modulating cannabinoid receptor signaling. It has been shown to interact with both CB1 and CB2 receptors, which are the two main receptors of the endocannabinoid system. This interaction can either enhance or inhibit the activity of these receptors, depending on the specific cell type and signaling pathway involved.

In addition to its role in the endocannabinoid system, Recombinant Human CNRIP1 has also been found to interact with other proteins and play a role in various cellular processes. For example, it has been shown to interact with the voltage-gated potassium channel Kv4.2, which is involved in regulating neuronal excitability. This interaction may contribute to the protein’s role in modulating neuronal activity.

Potential Applications of Recombinant Human CNRIP1

Recombinant Human CNRIP1 has been identified as a potential therapeutic target for various diseases, including neurological disorders and cancer. Studies have shown that this protein is dysregulated in several neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, and schizophrenia. Therefore, targeting CNRIP1 could potentially lead to the development of novel treatments for these conditions.

In addition, Recombinant Human CNRIP1 has been found to play a role in cancer progression. It has been shown to interact with the tumor suppressor protein p53, and its overexpression has been linked to increased cell proliferation and tumor growth. Therefore, targeting CNRIP1 could potentially be a promising strategy for cancer treatment.

Furthermore, Recombinant Human CNRIP1 has been studied as a potential biomarker for various diseases. Its expression has been found to be altered in several conditions, including obesity, diabetes, and cardiovascular diseases. This suggests that measuring CNRIP1 levels could be a useful diagnostic tool for these diseases.

Conclusion

Recombinant Human CNRIP1 is a 35 kDa protein that plays a crucial role in the endocannabinoid system. It interacts with cannabinoid receptors and other proteins, and its dysregulation has been linked to various diseases. Further research on this protein could potentially lead to the development of novel treatments and diagnostic tools for a range of disorders.